The global PD-L1 Biomarker Testing Market is expected to witness a robust CAGR of 9.14% from 2023 to 2033. The market is set to reach a valuation of US$ 1.58 billion by 2033, scaling up from an estimated US$ 659.6 million in 2023. Historically, the market for PD-L1 biomarker testing arrived at a value of US$ 597.9 million in 2022 while growing at a CAGR of 6.96% from 2017 to 2022.
As cancer diagnostics require specific technology and tools, PD-L1 biomarker testing observes high demand. Thus, the increasing cases of cancer and rising health awareness among the general population facilitate the growth of the PD-L1 biomarker testing market during the forecast period.
The detection of particular biomarkers, proteins, and other symptoms is required in cancer diagnostics. These biomarkers indicate the development of cancerous cells. The diagnostic process involves the use of specific devices and technology. PD-L1 is a protein that helps to keep the immune system in check and is found in higher concentrations in cancerous conditions. As cancer cases continue to rise and have a significant impact on society all over the world, the prospects for the PD-L1 biomarker testing market look bright in the upcoming years.
Get a PDF Sample with the Latest Market Insights @ https://www.futuremarketinsights.com/reports/sample/rep-gb-5897
Cancer is one of the leading causes of death in the world with surging prevalence across both developed and developing nations. The alarming rise in cancer rates has encouraged healthcare providers to reconsider treatment goals and focus on preventive care. In addition to this, rising research activities regarding the treatment of various cancer indications will augur well for the target market. The PD-L1 biomarker testing gains widespread application across various tumor types, including early-stage cancer detection. It also finds use in cancer immunotherapy. All of these factors are expected to aid the expansion of the PD-L1 biomarker testing market size during the projection period.
Key Takeaways:
- The obstacles in testing and identifying biomarkers along with their validation and implementation in molecular diagnostics are likely to limit the growth of the PD-L1 biomarker testing market.
- Based on the product type, the PD-L1 22C3 assay kit will dominate the global market with a share of 49.90% in 2023.
- By indication, the lung cancer category will generate high demand for the market due to its high prevalence.
- The PD-L1 biomarker testing market in the US is anticipated to account for 57.4% of the overall market share by 2033.
- The U.K will emerge as an attractive market for PD-L1 biomarker testing with a CAGR of 9.9% during the assessment period.
Have a Conversation with the Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-5897
Competitive Landscape
- F. Hoffmann – La Roche Ltd.
- Agilent Technologies, Inc.
- Abcam plc, Shuwein Biotech Co. Ltd.
- NeoGenomics Laboratories, Inc.
- HalioDx, Abcam plc
- Merck, Bristol-Myers Squibb
- AstraZeneca
Leading market players are concentrating on the development and launch of novel PD-L1 biomarkers for treatment purposes. These organizations focus on gaining quick approvals, government incentives, increasing investment in research and development activities, and engaging in other organic and inorganic business strategies to strengthen their market footprints.
Key Market Segments Covered in PD – L1 Biomarker Testing Industry Research
By Product:
- PD-L1 22C3 Assay Kit
- PD-L1 28-8 Assay Kit
- PD-L1 SP142 Assay Kit
- PD-L1 263 Assay Kit
Click here today to buy your full report @ https://www.futuremarketinsights.com/checkout/5897
By Indication:
- NSCLC
- Melanoma
- Renal Cell Carcinoma
- Gastrointestinal tract Malignancy
- Haematological Malignancies
- Ovarian Cancer
- Other
By End User:
- Hospitals
- Diagnostic Laboratories
- Cancer Research Institutes
About Future Market Insights (FMI)
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs
